Document:

Exhibit 10.1

 

Appendix C

 

Text of the Amended Letter of Indemnification
(in Connection with the 

Registration
Process)

 

BioLight Israeli Life Sciences Investments
Ltd.

 

Re: Letter of Indemnification

 

WHEREAS Pursuant to Section 136
of the Articles of Association of BioLight Israeli Life Sciences Investments Ltd. (the “Company”), the Company
may provide an undertaking in advance to indemnify an officer in the Company, in accordance with the conditions set forth in the
Articles of Association and the provisions of the Companies Law, 5759-1999; and

 

WHEREAS The Company has resolved
the resolutions required under any law for granting an undertaking in advance to indemnify officers of the Company, in accordance
with this Letter of Indemnification; and

 

WHEREAS You serve as an officer
of the Company;

 

Therefore, the Company hereby undertakes
towards you as follows:

 

		1.	Preamble,
Titles and Definitions

 

		1.1.	The
preamble of this Letter of Indemnification constitutes an integral part hereof.

 

		1.2.	The
titles in this Letter of Indemnification are provided for the purpose of convenience alone and shall not serve for the purpose
of interpretation of this Letter of Indemnification or any of its provisions.

 

		1.3.	Within
this Letter of Indemnification, the following terms shall have the definitions listed beside them:

 

	“Companies Law” -	The Companies Law, 5759-1999, as amended from time to time.
	 	 
	“Officer” -	As defined in the Companies Law, including any employee to which the Company shall decide to provide a letter of Indemnification.

  

     

     

    

  

	“Action” -	As defined in the Companies Law.

 

		“The
                           Articles of Association” -
                           	The
                                         Articles of Association of the Company as in effect from the date on which this Letter
                                         of Indemnification is provided.

  

     

     

    

   

		2.	Undertaking
to Indemnification

 

The Company hereby undertakes to indemnify
you, pursuant to the provisions of any law which may not be conditioned upon, and pursuant to the provisions of this Letter of
Indemnification, for any debt or expense as set forth in paragraphs (A), (B), (C) (D), (E) and (F) below, that was/shall be placed
on you or that you shall incur due to an action that you performed in your capacity in Israel, United States of America or other
country in the World as an officer of the Company and/or in the capacity of your position on behalf of the Company in the subsidiaries
and/or affiliated companies of the Company(including actions performed by you prior to the date of this Letter of Indemnification):

 

		(A)	A
financial debt placed upon you for the benefit of another person due to a judgment, including a judgment granted within a settlement
or an arbitration ruling approved by court.

 

		(B)	Reasonable
litigation expenses, including attorneys’ fees, that you incurred due to an investigation or proceeding conducted against
you by an authority authorized to conduct such an investigation or proceeding, and that is concluded without an indictment being
filed against you and without a financial sanction being placed on you in lieu of a criminal proceeding, or that will conclude
without an indictment being filed but with the placement of a financial sanction in lieu of a criminal proceeding for a crime
that does require evidence of mens rea. In this paragraph, “the conclusion of a proceeding without an indictment
being filed in a matter in which a criminal investigation was initiated” and “a financial sanction in lieu of a criminal
proceeding” are as defined in Section 260(a)(1a) of the Companies Law.

 

		(C)	Reasonable
litigation expenses, including attorney’s fees incurred or that you are charged by a court, in a proceeding filed against
you by the Company or on its behalf or by another person or in a criminal indictment from which you are acquitted or a criminal
charge in which you are charged with an offense that does not require proof of Criminal Intent.

 

		(D)	Expenses
expended by you or imposed on you in connection to administrative proceedings involving you, including attorney fees.

 

		(E)	A
payment which you are obligated to make to an injured party as set forth in Section 52(54) of the Israeli Securities Law, 1968,
as amended (the "Security Law").

 

		(F)	Any
other monetary liability or other expense that the Company is permitted by law to indemnify you.

 

The undertaking to provide indemnification
as stated in subsection (A) above is limited to the types of events set forth in the addendum to this Letter of Indemnification
(the “Addendum”), which, in the opinion of the Company’s board of directors, may be anticipated, or any
part thereof, provided that the Maximum Indemnification Amount does not exceed the amount set forth in Section 4 below.

  

    3 

     

    

   

		3.	Exclusions

 

The indemnification will not apply in any
of the cases set forth below:

 

		3.1.	A
breach of a fiduciary duty vis-a-vis the Company or another entity, excluding, to the extent permitted by law, a breach of a fiduciary
duty performed in good faith for which you had a reasonable basis to assume that the action would not harm the interests of the
Company or the other entity.

 

		3.2.	A
breach of a duty of care, performed intentionally or recklessly, excluding if performed with negligence alone.

 

		3.3.	An
action with intent to derive unlawful personal profit.

 

		3.4.	A
sanction or fine that you are charged.

 

		3.5.	A
claim (including a counter-claim of the Company following a claim filed by an officer against the Company) that the Company won
against the officer.

 

		4.	Indemnification
Amount

 

The aggregate indemnification amount that
the Company will pay for each of the officers of the Company under letters of Indemnification issued and/or that will be issued
by the Company will not exceed USD 10 million or an amount equivalent to 25% of the Company’s equity pursuant to the most
recent annual financial statements of the Company as of the actual indemnification date, whichever is higher (the “Maximum
Indemnification Amount”).

 

It is hereby clarified that the payment
of the indemnification amount under this Letter of Indemnification will not harm your right to receive insurance payments for types
of events set forth in the Letter of Indemnification that are insured by an insurance company, as received by the Company for you,
if any, in the framework of the Company’s officer liability insurance, subject to the provisions of Section 6.6 below.

 

In the event that the total indemnification
payments that the Company is required to pay on any date, in addition to the total indemnification payments paid thereby by the
same date pursuant to letters of Indemnification, exceeds the Maximum Indemnification Amount, the Maximum Indemnification Amount
or the balance thereof, as applicable, will be divided between officers that are eligible for indemnification as stated and that
was not yet paid thereto by the same date, such that the indemnification amount actually received by each of the aforesaid officers
will be calculated based on the ratio between the indemnification amount that is owed to each of the officers and between the aggregate
indemnification amount that is owed to each of the aforesaid officers on the same date for the indemnification demands issued to
the Company.

  

    4 

     

    

   

In the event that the Company pays indemnification
amounts to officers of the Company in the amount of the Maximum Indemnification Amount, the Company will not bear additional indemnification
amounts unless the increase of the Maximum Indemnification Amount is approved by the competent organs of the Company.

 

		5.	Advances
and Interim Payments

 

Upon the occurrence of an event for which
you are entitled to indemnification under this Letter, the Company will provide you with the amounts that you require to cover
expenses and other payments involved in handling any legal matter against you that is related to the same event, such that you
will not be required to finance them independently, all subject to the provisions of this Letter of Indemnification.

 

In the event that the Company pays you,
or pays in your place, any amounts in the framework of this Letter of Indemnification in connection with a legal proceeding as
stated, and it is thereafter determined that you are not entitled to indemnification from the Company for the same amounts under
the provisions of the law or this Letter of Indemnification, the provisions of Section 6.6 below will apply to the same amounts.

 

As part of the Company’s undertaking
as stated above, the Company will provide securities required or guarantees that the officer will be required to provide under
interim decisions of a court or arbitrator, including for the replacement of attachments imposed on assets of the officer, provided
that the total securities (including forfeited securities), in addition to the amounts received / that will be received by an officer
under this Letter of Indemnification, will not exceed the amounts set forth in this Letter of Indemnification.

 

		6.	Terms
of the Indemnification

 

Without derogating from the above, the
provision of the indemnification under this Letter of Indemnification is subject to the following terms:

 

		6.1.	You
are required to notify the Company in writing of any legal proceeding initiated against you or any concern or threat of a proceeding
as stated being initiated in connection with any event for which the indemnification may apply (hereinafter: a “Legal
Proceeding”), immediately after being first made aware thereof. Additionally, you are required to immediately transfer
to the Company and/or any party of which it shall inform you, any document provided to you and/or in your possession in connection
with the same legal proceeding.

  

    5 

     

    

   

		6.2.	Legal
Handling

 

The Company may, but is not required to,
participate and/or undertake handling the legal proceeding and/or transfer the handling thereof to any attorney selected by the
Company for the same purpose (other than an attorney who you reject for reasonable reasons), at its expense and responsibility.
If within 15 days from the receipt of your notice as stated in Section 6.1 above, the Company does not undertake to handle the
legal proceeding or if you object to representation by the attorney as stated for reasonable reasons, you may select an attorney
to handle the legal proceeding, and the Company will indemnify you for the legal fees of the other attorney, provided that the
Company believes that the same amount is reasonable under the circumstances.

 

In the event that the Company undertook
to handle the legal proceeding, the Company will not be required to pay you indemnification for litigation expenses incurred with
respect to managing the legal defense.

 

The Company and/or the attorney as stated
will act in order to conclude the aforesaid legal proceeding. An attorney appointed by the Company will owe a duty of loyalty to
the Company and to you. In the event that a conflict of interests arises between you and the Company in your defense in a legal
proceeding, you will inform the attorney thereof, and may appoint an attorney on your behalf to handle your defense, and the provisions
of this Letter of Indemnification will apply to expenses that you incur in the appointment of an attorney as stated.

 

The Company may not conclude the legal
proceeding by way of settlement and/or arrangement as a result of which you are not indemnified under this Letter of Indemnification
and/or that prevents your entitlement for payments in the framework of the Company’s officer insurance policy acquired, if
any, by the Company, without your prior written consent thereto. Additionally, the Company may not transmit the dispute at the
subject of the legal proceeding for a decision by way of arbitration, settlement or mediation without your prior written consent,
provided that you do not refuse to provide consent as stated other than for reasonable reasons provided to the Company in writing.

 

Notwithstanding the above, the Company
may not conclude a legal proceeding as stated by way of settlement and/or an arrangement and/or conclude the dispute at the subject
of the legal proceeding by way of arbitration, settlement or mediation in the event in which the legal proceeding includes criminal
charges against you, unless your provide your prior written consent thereto, at your exclusive discretion and without requiring
you to explain your opposition.

  

    6 

     

    

   

		6.3.	Cooperation

 

You are required to fully cooperate with
the Company and its legal counsel, and provide them with or sign any document required for the purpose of handling the legal proceeding
and your representation with respect thereto.

 

Additionally, you are required to uphold
all of the instructions for insured parties under any policy for officer liability of the Company and/or in which you engage, that
is reasonably required of you in the framework of the treatment in connection with the legal proceeding, provided that the Company
or the insurance company ensures that your expenses involved in the same are covered, such that you are not required to pay them
independently and subject to the provisions of this Letter of Indemnification.

 

		6.4.	Coverage
of Charges and Expenses

 

Whether the Company exercises its right
as stated in Section 6.2 above or otherwise, the Company will ensure to cover all of the charges and expenses set forth in Section
2 above, such that you will not be required to pay or finance them on your own, without derogating from the indemnification to
which you are entitled under this Letter of Indemnification.

 

		6.5.	Non-Application
of Indemnification in Settlement of Admission

 

Indemnification in connection with a legal
proceeding against you, as stated in this Letter of Indemnification, will not apply with respect to any amount owed from you to
a plaintiff in the event of a settlement or arbitration, unless the Company has agreed to the same settlement or arbitration, as
applicable, in advance and in writing, and the Company will not refrain from providing its consent other than for reasonable reasons.

 

Additionally, the indemnification will
not apply in the case in which you provided an admission in a criminal charge for an offense that does not require proof of mens
rea, unless the Company provided its prior written consent to your admission.

 

		6.6.	Indemnification
in the event of Indemnification or Insurance from a Third Party

 

The Company will not be required to pay,
under this Letter of Indemnification, amounts for any event if the said amounts were paid to you or in your place in the framework
of the Company’s officer liability insurance policy or in the framework of indemnification provided to you by a third party
that is not the Company, but only in the case in which the amount received from the insurer or third party as stated does not cover
an expense or charge to which you are subject as stated. In such a case, the Company undertakes to pay only the difference between
the amount of the charge or expense to which you are subject as stated in Section 2 above, and between the amount received by the
insurer or any third party, provided that the indemnification amount that the Company is charged does not exceed the Maximum Indemnification
Amount. For the avoidance of doubt, it is hereby clarified that this indemnification undertakes does not constitute an agreement
in favor of a third party, and the insurer will not have the right to demand participation from the Company for payment that the
insurer is required to make to the insured party, if any, under an insurance policy, excluding a deductible set forth in the policy
as stated.

  

    7 

     

    

   

		6.7.	Payment
of the Indemnification

 

Upon your request for any payment in accordance
with this Letter of Indemnification, the Company will take all of the actions required for payment thereof, and will act to receive
all of the approvals required under any law in connection therewith, if required. If approval for any payment is required, and
approval as stated is not received for any reason, the payment as stated will be subject to approval of the court, and the Company
will act to obtain said approval.

 

		6.8.	Return
of Indemnification Amounts Paid

 

In the event in which the Company paid
to you or in your place any amounts in the framework of this Letter of Indemnification, and thereafter it is discovered that you
are not entitled to indemnification from the Company for the same amounts, the amounts will be considered a loan provided to you,
and you will be required to return the same amounts in addition to interest and linkage differentials in the minimum amount set
forth by law.

 

In the event in which it is discovered
that the charge for which the Company paid indemnification amounts is cancelled or its amount is lowered for any reason, you are
required to assign all of yours rights to return the aforesaid amount and perform all of the actions required in order for the
same assignment to be effective. In the event that you fail to do so, you are required to return the aforesaid amounts to the Company
in addition to interest and linkage differentials in the amount and for the period for which you are entitled to receive the same
amount from the plaintiff.

 

		7.	Term
of the Indemnification

 

The undertaking of the Company under this
Letter of Indemnification will remain for your credit and/or the credit of your estate without limitation in time, even after the
termination of your service as an officer of the Company and/or your employment by the Company, as applicable, provided that the
actions for which the indemnification is provided to you were performed during the term of your service at the Company as an officer
and/or your employment by the Company, regardless of the date of discovery of the event for which you were entitled to indemnification
under this document.

  

    8 

     

    

  

		8.	Miscellaneous

 

		8.1.	The
Company may, at its exclusive discretion and at any time, terminate its indemnification undertaking under this document or change
any of its terms, including the Maximum Indemnification Amount, types of events to which it applies and the like, insofar as it
relates to events that occur after the date of the change, provided that prior written notice is provided to officers of the intent
as stated at least 30 days before the date on which the aforesaid decisions enters into force. For the avoidance of any doubt,
it is hereby clarified that any such decision that may worsen the terms of this undertaking or terminate it will not have retroactive
application and the Letter of Indemnification before its change or termination, as applicable, will continue to apply and be in effect
for all intents and purposes with respect to any event that occurred before the change or termination, even if the date of the
discovery of an event as stated occurs after the change or termination of the Letter of Indemnification.

  

    9 

     

    

 

 

 

		8.2.	The
undertakings of the Company under this Letter of Indemnification will be interpreted broadly and in a manner enabling their fulfillment,
to the extent permitted by law, for the puipose for which it was intended. In the event of a conflict between any provision of
this Letter of Indemnification and the provisions of any law that cannot be conditioned upon, the provisions of the aforesaid
law will prevail, but the above will not harm or derogate from the validity of the other provisions of this Letter of Indemnification.

 

		8.3.	This
Letter of Indemnification will not derogate from the Company’s right to decide to retroactively indemnify under the provisions
of the law.

 

		8.4.	This
Letter of Indemnification will enter into force upon the delivery to the Company of this Letter of Indemnification, when signed
by you in the place designated for your signature.

 

		8.5.	For
the avoidance of doubt, it is hereby clarified that this Letter of Indemnification does not constitute an agreement in favor of
a third party and cannot be transferred and/or assigned.

 

		8.6.	No
waiver, delay, inactive on time or extension by the Company or by you will be interpreted under any circumstances as a waiver
of its rights under this Letter of Indemnification and under any law, and will not prevent the same party from taking all of the
legal and other actions required for the realization of its rights as stated.

 

		8.7.	The
Addendum to this Letter of Indemnification constitutes an integral part hereof.

 

		8.8.	The
law applicable to this Letter of Indemnification is the law of the State of Israel and the competent courts of Tel Aviv have the
exclusive jurisdiction to hear disputes arising from the application of this Agreement.

 

In witness whereof, the Company affixes
its signature on_______:

 

	 	 
	 	BioLight Israeli Life Sciences Investments Ltd.

 

    10 

     

    

  

 

 

I hereby confirm receipt of this Letter
of Indemnification, and undertake to act in accordance with its provisions, including the provisions of Section 6 above.

 

	 	 
	 	 
	Name of the Director/Officer

  

    11 

     

    

  

 

 

Addendum

 

1.          Actions
of the Company connected to the Company’s field of business in the development of pharmaceutical and/or medical devices and/or
any Action connected directly and/or indirectly to the performance of the above Actions.

 

2.          Occurrences
in connection with investments in or by the Company and/or subsidiary and/or affiliate in other corporations whether before and/or
after the investment is made, entering into the transaction, the execution, development and monitoring thereof, including actions
taken in the name of the Company and/or subsidiary and/or affiliate by a director, officer, employee and/or board observer of the
corporation which is the subject of the transaction and the like;

 

3.          The
offer and/or issuance of securities of the Company by the Company and/or any shareholder to the public in Israel, the U.S. or any
other country in the world and /or privately, including under prospectuses, notices, reports and purchase offers.

 

4.          An
action and/or omission arising from the Company being a public company and/or the offer of its securities to the public, whether
in the U.S. or elsewhere, including the submission of reports.

 

5.          An
action filed against the officer by a customer, supplier, contractor or any other third party that conducts any kind of business
with the Company or its subsidiaries or by an entity or authority that operates under any law.

 

6.          Actions
taken in connection with labor relations and/or employment matters (including employment-related benefits) in the Company and/or
subsidiary and/or affiliate.

 

7.          Actions
relating to the promotion, offering and/or support of the products, solutions and technologies in the fields of operation of the
Company, any of its subsidiaries or affiliates as shall exist from time to time.

 

8.          Actions
taken in connection with the intellectual property of the Company and/or subsidiary and/or affiliate and its protection, including
the registration or assertion of rights to intellectual property and the defense of claims related to intellectual property or
any claim or demand made for actual or alleged infringement, misappropriation, or misuse of any third party's intellectual property
rights by the Company, its subsidiaries or affiliates, including without limitation confidential information, patents, copyrights,
design rights, service marks, trade secrets, copyrights, and misappropriation of ideas by the Company, its subsidiaries or affiliates.

  

    12 

     

    

 

 

  

9.          A
transaction in which the Company is a party, including in connection with the receipt of credit, a sale, lease, transfer or purchase
of assets or liabilities of the Company, purchase of securities of other corporations or the receipt of rights in other corporations,
the receipt and/or provision of an option for each of the above and an action that is directly or indirectly involved in the transaction
as stated.

 

10.         Any
claim or demand made in connection with any transaction not in the ordinary course of business of either the Company or the party
making such claim (including any transaction with directors or officers of the Company or any controlling shareholder of the Company).

 

11.         Any
administrative, regulatory or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations,
proceedings or notices of noncompliance or violation by any governmental entity (in Israel or abroad), including the Office of
the Chief Scientist or the Investment Center of the Israeli Ministry of Industry and Commerce, the Israeli Antitrust Authority
or the Israel Securities Authority, or other person alleging the failure to comply with any statute, law, ordinance, rule, regulation,
order or decree of any governmental entity applicable to the Company and/or Subsidiary, or any of their respective businesses or
operations.

 

12.         Any
acts in regard of invasion of privacy, participation and/or non-participation at Board meetings and/or voting and/or abstention
from voting at Board meetings, approval of corporate actions, claims of failure to exercise business judgment.

 

13.         Claims
of failure to exercise business judgment and a reasonable level of proficiency, expertise and care in regard of the Company's business.

 

14.         Violations
of laws requiring the Company to obtain regulatory and governmental licenses, permits and authorizations in any jurisdiction.

 

15.         Granting
of liens on Company assets and granting guarantees on behalf of the Company.

 

16.         Any
claim or demand filed by a creditor of the Company with respect to funds loaned thereby to the Company or debts of the Company
towards it.

 

17.         Any
claim or demand filed by a third party following bodily or property damage, including loss of use thereof, during an action or
omission attributed to the Company or its employees, agents or individuals that are required to act on its behalf.

 

18.         An
expression, statement, including presenting an opinion, made in good faith by the officer during its function and by virtue of
its position, including in the framework of meetings of the board of directors, any of its committees or general meetings of the
Company.

 

    13 

     

    

  

 

 

19.         A structural
change or reorganization, including without derogating from the above, a merger, division, change to the Company’s capital,
establishment of a subsidiary, liquidation or sale to third parties.

 

20.         Any
legal proceeding on matters related, directly or indirectly, to environmental protection or the provisions of the law or procedures
related to pollution, protection of health, use or handling of hazardous materials and the like.

 

21.         Non-disclosure
or failure to supply any type of information of the date required under law or in connection with misleading or incomplete disclosure
of information as stated to third parties, including the tax authorities, national insurance authorities, local authorities, Ministry
of Environmental Protection and any other government or institutional entity, in the U.S., Israel and elsewhere..

 

22.         Any
action and/or omissions of the Company or its employees or officers with respect to payment, reporting or documentation of documents
in connection with any federal, state, municipal or foreign authorities, including payment of any taxes or charges, national insurance
payments, salaries or a delay in any payments, including payments of wages to employees, interests and linkage differentials.

 

23.         Any
action that leads to failure to hold proper insurance arrangements.

 

24.         The
filing of a report and/or announcement required by the Companies Law and/or any securities law which is applicable or may be applicable
to the Company from time to time, including the U.S. Securities Laws, including the regulations pertaining to these laws, the Israeli
Securities Law - 1968, and/or according to rules and/or regulations adopted by the NASDAQ or any other stock exchange and/or securities
market and/or any law of any other country pertaining to these issues and/or the failure to file such a report and/or announcement,
and/or actions relating to tender offers of the Company, including actions relating to delivery of opinions in relation thereto.

 

25.         Any
decision regarding a distribution, as defined in the Companies Law, including a distribution pursuant to a court order, and/or
repurchase of shares or returns of capital or loans of the Company.

 

26.         Events
related to the preparation and/or approval of the Company’s financial statements.

 

27.         Events
related, directly or indirectly, to antitrust laws, including restrictive arrangements and/or monopolies and/or divisions and/or
mergers.

 

28.         Any
of the forgoing actions or decisions relating or otherwise applicable to any subsidiary or affiliate of the Company, as may exist
from time to time.

 

29.         Any
claim or demand, not covered by any of the categories of events described above, which, pursuant to any applicable law, a director
or officer of the Company may be held liable to any government or agency thereof, or any person or entity, in connection with actions
taken by such director or officer in such capacity.

 

    14Exhibit 10.2

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

Exhibit D

 

[* * *]

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[* * *] – CONFIDENTIAL TREATMENT REQUESTED

 

 

    	 

    	 

    

 

 

MUTUAL
NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (the “Agreement”) is made effective June 13, 2011 (the
"Effective Date” by and between Aerie Pharmaceuticals, Inc., having its principal place of business at 1140 Route 22
East, Bridgewater, NJ 08807 ("Aerie") and Bio Light Israeli Life Sciences Investments Ltd., having a place of business
at Paz Tower 7th Floor, 5-7 Shoham St., Ramat Gan Israel, 52521, on behalf of itself and its subsidiaries and affiliates ("Bio-Light")
(collectively, “the parties”). The parties are evaluating the possibility of entering into a contractual arrangement
relating to the evaluation by Bio-Light of Aerie's ocular drug implant/insert technology. In furtherance of that evaluation process
and for such other purposes as the parties may agree in writing, the parties may wish to disclose to each other Proprietary Information
(as described below). The parties acknowledge and agree that their relationship with respect to such discussions and other exchanges
of information is one of mutual trust and confidence and that both parties will have, through such discussions and other exchanges
of information, access to Proprietary Information (as defined below). The parties further agree that it and each of its officers,
directors, employees, agents, accountants and counsel will maintain the confidentiality of all such Proprietary Information as
follows: 1. Proprietary Information. a. Definition. “Proprietary Information” for the purposes of this Agreement,
shall mean all information and know-how, whether or not in writing and whether or not patentable or protectable by copyright or
the law of trade secrets, disclosed by one party (the "Disclosing Party”) to the other party (the "Receiving Party")
and relating to the business, technical, or financial affairs of the Disclosing Party or its subsidiaries, affiliates, customers,
potential customers, suppliers or potential suppliers. Proprietary Information may include, by way of illustration and not limitation,
any invention, product, formula, method, technique, composition, compound, project, development, plan, vendor information, customer
information, apparatus, equipment, trade secret, process, research materials, reports, clinical data, financial data, technical
data, computer program, software, software documentation, hardware design, technology, marketing or business plan, forecast, unpublished
financial statement, budget, license, price, cost and personnel data. Failure to mark or designate any Proprietary Information
as confidential or proprietary shall not affect its status as Proprietary Information under this Agreement. b. Exclusions and
limitations. Notwithstanding the foregoing, Proprietary Information shall not include information that (i) has become public knowledge
through legal means without fault by the Receiving Party, (ii) is already public knowledge prior to the Disclosing Party’s
disclosure of the same to the Receiving Party, or (iii) is known to the Receiving Party prior to the disclosure of the same pursuant
to this Agreement as evidenced by contemporaneous documentation; (iii) is disclosed to the receiving party by a third party who
is not in breach of an obligation of confidentiality; (iv) was or is independently developed by the receiving party without use
of the Confidential Information disclosed by the disclosing party as evidenced by contemporaneous documentation; (v) is disclosed
pursuant to a court order, or to the extent required under any applicable law, including any securities laws or stock exchange
rules. In addition, the Receiving Party shall be entitled to release the Disclosing Party’s Proprietary Information in order
to prosecute or defend any claim under this Agreement, or pursuant to an order of a court or government agency, provided, however,
in the case of release pursuant to this sentence the Receiving Party shall limit the release to the greatest extent reasonably
possible under the circumstances and shall have provided the Disclosing Party with sufficient advance notice to permit the Disclosing
Party to seek a protective order or other order protecting its Proprietary Information from such disclosure.

 

    	 

    	 

    

 

2.
Obligations. a. The Receiving Party will use the same degree of care in safeguarding the Proprietary Information as it uses for
its own confidential or like information, and no less than a reasonable degree of care, and shall restrict disclosure of the Disclosing
Party’s Proprietary Information to those of its employees who have a need to know the same in furtherance of the purposes
of this Agreement. b. The Receiving Party agrees that all Disclosing Patty Proprietary Information shall remain the exclusive
property of the Disclosing Party to be used by the Receiving Party only for the purposes of expressly contemplated by this Agreement.
c. The Receiving Party further agrees that during the term of this Agreement and for the period of five (2) years from the date
of the last disclosure under this Agreement, it will not, either directly or through others, solicit or attempt to solicit any
employee of the Disclosing Party to become an employee, consultant or independent contractor to or for the Receiving Party. 3.
General. a. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement. b. No delay or omission by either party in exercising any right under this Agreement
will operate as a waiver of that or any other right. A waiver or consent given by either party on any one occasion is effective
only in that instance and will not be construed as a bar to or waiver of any right on any other occasion. c. This Agreement is
governed by and will be construed in accordance with the laws of the State of New York, USA, without regard to conflicts of law
principles. Any conflict arising out of this Agreement shall be submitted to the exclusive jurisdiction of the competent courts
of the city of New York. d. Both parties acknowledge that breach of the foregoing obligations may cause injury to the Disclosing
Party and that the Disclosing Party, without the requirement of posting bond or other security, may seek and obtain injunctive
or other equitable relief against such breach or threatened breach without prejudice to any other remedies which may be available
to it.

 

 

    	 

    	 

    

 

 

e. Any notice required
or desired to be given under this Agreement by one party to the other shall be in writing and shall be deemed to have been duly
given upon delivery: if manually delivered on the same business day; or, if mailed by registered or certified mail, postage prepaid,
after five (5) days from the date of mailing; or if by facsimile transmission which gives the sender proof of delivery, on the
first business day after such transmission, to the respective party’s address as set forth above or to such other address
or fax number of which notice has been given in the manner above provided. f. This Agreement shall be effective as of the Effective
Date and will continue in effect until terminated by ninety (90) days written notice of either party to the other. The obligations
of confidentiality hereunder in respect of any Proprietary Information shall survive the termination or expiration of this Agreement,
and shall terminate five (5) years from the date of the this Agreement's termination or expiration. This Agreement constitutes
the entire agreement between the parties hereto concerning the subject matter hereof and supersedes any prior or contemporaneous
agreements and understandings concerning the subject matter hereof BOTH PARTIES HAVE READ ALL OF THE PROVISIONS OF THIS AGREEMENT
AND UNDERSTAND AND AGREE TO EACH OF SUCH PROVISIONS. AERIE PHARMACEUTICALS, INC BIO-LIGHT LIFE SCIENCE INVESTMENT LTD. By:/s/
Thomas Forski By: /s/ Suzana Natium - Zilberberg Name Thomas Forski Name Suzana Natium – Zilberberg Title Director, Clinical
Project Management and Controling Title CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]